EsoBiotec's ESO-T01, an in vivo BCMA CAR-T therapy, has dosed its first patient in a Phase 1 investigator-initiated trial in China for relapsed/refractory multiple myeloma.
The FDA issued a CRL for Atara Biotherapeutics' tabelecleucel due to third-party manufacturing issues, not efficacy or safety data, delaying potential approval for EBV+ PTLD.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.